Form 4: Dianthus Therapeutics EVP Executes Stock Option Plan

EVP and Head of R&D Simrat Randhawa exercised stock options and sold shares under a pre-established Rule 10b5-1 trading plan.

Summary

• Simrat Randhawa, EVP and Head of R&D at Dianthus Therapeutics, exercised options for 26,530 shares of common stock.
• The exercise prices for these options ranged from $8.44 to $22.07 per share.
• Following the exercise, the reporting person sold 26,530 shares at weighted average prices between $89.72 and $91.37 per share.
• The transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on August 14, 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transactions were pre-planned and represent routine portfolio management by an executive.

Positives

• The executive maintains a remaining beneficial ownership of 4,000 shares of common stock.
• The transactions were executed under a pre-planned Rule 10b5-1 program, indicating a systematic approach to liquidity rather than reactive selling.

Negatives

• The executive reduced their direct equity stake in the company through the sale of 26,530 shares.

Risks

• Continued reliance on Rule 10b5-1 plans for liquidity may signal future periodic divestments by key management personnel.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this disclosure.

Industry Context

StockSavvy.ai notes that insider selling via 10b5-1 plans is a standard practice for biotech executives to realize gains from equity-based compensation, and does not necessarily reflect a change in sentiment regarding the company's clinical pipeline or commercial prospects.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for corporate insiders to avoid potential conflicts of interest or allegations of insider trading.
• The scale of the transaction is consistent with typical executive compensation liquidity events in the mid-cap biotechnology sector.

Stakeholder Impact

• Shareholders should view this as a routine liquidity event for the executive rather than a signal of operational change.

Next Steps

• Continued monitoring of future Form 4 filings for further insider activity.

Key Dates

Keywords

Dianthus Therapeutics, DNTH, Insider Trading, Form 4, Stock Options, Biotech, Executive Compensation